14 December 2021
\n \n \n \nThe two companies share the same goals, to improve the lives of those dealing with liver disease.
\n \n\n \n \n22 November 2021
\n \n \n \nHelping people get the answers they need to make more informed decisions across the cancer continuum.
\n \n\n \n \n15 November 2021
\n \n \n \nCyanoCapture aims for scalable, low-cost, biological carbon capture using genetically-modified algae, known as cyanobacteria.
\n \n\n \n \n5 November 2021
\n \n \n \nThe technology used to identify this gene has been exclusively licensed to Nucleome, highlighting the competitive advantage of Nucleome\u2019s platform in the discovery of genetic targets for innovative precision medicine development.
\n \n\n \n \n1 November 2021
\n \n \n \nKyttaro is developing innovative therapeutics to treat hypertriglyceridemia, atherosclerotic cardiovascular disease and inflammatory and neurogastroenterology conditions.
\n \n\n \n \n21 October 2021
\n \n \n \nRecipients of the OBN Awards are considered to have made an outstanding and valuable contribution to their field, which is why Ochre Bio is thrilled to have made the cut at this early stage of its life.
\n \n\n \n \n4 August 2021
\n \n \n \nProceeds to support expansion and advancement of PepGen\u2019s pipeline of Enhanced Delivery Oligonucleotide (EDO) therapies for neuromuscular and neurologic diseases.
\n \n\n \n \n22 July 2021
\n \n \n \nAfter a highly successful start, Theolytics is ready for the next step in its journey and is moving to The Oxford Science Park. The company will be the first tenant moving into the newly refurbished Sherard Building.
\n \n\n \n \n24 June 2021
\n \n \n \nMediMabBio has started global clinical trials of its flagship pipeline. After securing R&D funding through a Series A round earlier this year, it will collaborate with a UK clinical trial institution to conduct joint research to develop a treatment for liver cancer.
\n \n\n \n \n17 June 2021
\n \n \n \nThe funding will be used to advance the development of Ochre Bio\u2019s RNA therapies and expand its deep phenotyping platform to identify and validate new liver targets.
\n \n\n \n \n13 June 2021
\n \n \n \nOXvax Ltd. is a spin-out company from the University of Oxford focused on developing an advanced next-generation dendritic cell vaccine platform for treating solid tumour cancers.
\n \n\n \n \n10 June 2021
\n \n \n \nAlchemab Therapeutics, a former resident company at Oxford's BioEscalator, has won Best Start-up Biotech Company at the prestigious 2020 OBN Awards, presented on Friday 11 June at the Royal Lancaster in London.
\n \n\n \n \n31 May 2021
\n \n \n \nMoA Technology is in the process of moving to the Bellhouse Building at the Oxford Science Park to continue its mission to provide farmers with a diverse choice of innovative technologies for weed control.
\n \n\n \n \n29 April 2021
\n \n \n \nAlchemab Therapeutics, the antibody therapeutic start-up backed by SV Health Investors, has graduated from the BioEscalator after 18 months in the Innovation Labs.
\n \n\n \n \n26 April 2021
\n \n \n \nMoA Technology, a spin-out company from Oxford University\u2019s Department of Plant Sciences, has secured an additional \u00a35M funding for its series A round to support the expansion and acceleration of its discovery programme.
\n \n\n \n \n16 April 2021
\n \n \n \nThe biotech company, which joined the BioEscalator Innovation Lab as a new start-up in December 2019, secures Series A funding to advance its novel platform for identifying disease-modifying antibody therapeutics.
\n \n\n \n \n23 March 2021
\n \n \n \n\n \n \n10 March 2021
\n \n \n \nAccunea is pioneering the next generation of continuous, real-time organ function monitoring to ensure every transplant counts.
\n \n\n \n \n26 February 2021
\n \n \n \nBioEscalator biotech, MediMab Biotherapeutics, secures Series A funding to advance two immuno-oncology candidate therapeutics in pre-clinical studies.
\n \n\n \n \n12 January 2021
\n \n \n \nThe partnership deal, worth over \u20ac876M, will enable Enara Bio to lead the discovery and validation of Dark Antigens to target lung and gastrointestinal cancers.
\n \n\n \n \n